CFAP410 and Retinal dystrophy: A gene therapy for CFAP410-related retinal dystrophy would be a good candidate, since the cDNA size of 1.1kb is well within the packaging capacity of the adeno-associated viral vector—the most established vector for retinal gene supplementation (25,26).